CD4 and neoplasm: Comparing control tumor-bearing mice without treatment, sunitinib administration led to the slight reduction in the frequency of CD4+ T cells from 68% to 67% (Figure 3A and 3B), but small increase of CD4+ T cells seen in sorafenib-treated mice from 68% to 70% (Figure 3C and 3D).